Published in Cancer Invest on January 01, 1996
Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes. Microbiol Mol Biol Rev (1998) 3.26
Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression. J Exp Med (1997) 1.73
Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. J Virol (1999) 1.68
Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol (2002) 1.66
RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection. J Virol (1998) 1.44
Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice. J Exp Med (2000) 1.35
Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. J Exp Med (1999) 1.31
Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer (2009) 1.12
The serine proteinase inhibitor (serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon alpha/beta priming. J Exp Med (1998) 1.08
Thioredoxin reductase mediates cell death effects of the combination of beta interferon and retinoic acid. Mol Cell Biol (1998) 1.06
Modelling dynamics of the type I interferon response to in vitro viral infection. J R Soc Interface (2006) 0.99
The polyoma virus T antigen interferes with interferon-inducible gene expression. Proc Natl Acad Sci U S A (1998) 0.96
Nicotine, IFN-γ and retinoic acid mediated induction of MUC4 in pancreatic cancer requires E2F1 and STAT-1 transcription factors and utilize different signaling cascades. Mol Cancer (2012) 0.89
Inhibition of infection and replication of human herpesvirus 8 in microvascular endothelial cells by alpha interferon and phosphonoformic acid. J Virol (2004) 0.89
The interferon-inducible murine p48 (ISGF3gamma) gene is regulated by protooncogene c-myc. Proc Natl Acad Sci U S A (1997) 0.87
Characterization and mapping of the double-stranded regions involved in activation of PKR within a cellular RNA from 3T3-F442A cells. Nucleic Acids Res (1997) 0.87
Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma. Cytokine Growth Factor Rev (2007) 0.80
Functional Characterization of Interferon Regulation Element of Hepatitis B virus Genome In Vivo. Indian J Virol (2012) 0.78
Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer. Cytokine (2016) 0.76
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 3.73
Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci U S A (1996) 2.45
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2004) 2.17
Human polyomavirus infections with JC virus and BK virus in renal transplant patients. Ann Intern Med (1980) 2.07
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res (1998) 2.04
In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol (1996) 1.98
Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res (1987) 1.87
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Physiocochemical and serological studies. J Gen Virol (1971) 1.78
Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. J Interferon Res (1989) 1.74
Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res (2001) 1.73
Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res (1986) 1.70
Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol (1987) 1.65
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies. J Gen Virol (1971) 1.56
Concepts of fever: recent advances and lingering dogma. Clin Infect Dis (1997) 1.50
A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. J Immunol (1991) 1.47
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol (1987) 1.42
Rapid detection and identification of JC virus and BK virus in human urine by using immunofluorescence microscopy. J Clin Microbiol (1980) 1.42
Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol (1989) 1.41
Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer (1989) 1.38
The interferon refractory state: in vivo and in vitro studies of its mechanism. J Immunol (1971) 1.34
Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia (1989) 1.33
Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res (1982) 1.25
Beta interferon inhibits Toxoplasma gondii growth in human monocyte-derived macrophages. Infect Immun (1989) 1.20
A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. J Clin Invest (1990) 1.20
Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer (1975) 1.16
Streptovaricins inhibit focus formation by MSV (MLV) complex. Nat New Biol (1971) 1.14
Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer (2006) 1.13
Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon. J Immunol (1979) 1.09
Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol (1991) 1.08
Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol (1987) 1.08
Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res (1997) 1.06
Enhancement of T cell cytotoxic responses by purified human fibroblast interferon. J Immunol (1978) 1.05
Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol (1996) 1.05
Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res (1992) 1.04
Aquanititave semimicro, semiautomated colorimetric assay for interferon. J Lab Clin Med (1977) 1.04
Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. Ann Intern Med (1982) 1.03
Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene (2007) 1.03
Selective inhibition by streptovaricin of splenomegaly induced Rauscher leukaemia by virus. Nat New Biol (1971) 1.03
Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med (1992) 1.03
Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. J Biol Chem (1996) 1.02
Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst (1989) 1.02
Mechanistic studies of polyene enhancement of interferon production by polyriboinosinic-polyribocytidylic acid. Antimicrob Agents Chemother (1978) 1.01
Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res (1993) 0.99
Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity. J Interferon Res (1990) 0.98
The effect of interferon on the metabolism of LDLs. Arterioscler Thromb (1992) 0.98
Studies on the poxvirus Cotia. J Gen Virol (1980) 0.97
Measurement of 2',5'-oligoadenylate synthetase in patients receiving interferon-alpha. J Interferon Res (1985) 0.97
o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement. Cancer (1978) 0.97
A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth. Oncogene (2012) 0.96
Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Semin Hematol (1994) 0.96
Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res (1989) 0.94
Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro. J Interferon Cytokine Res (1997) 0.93
2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals. AIDS (1991) 0.93
Low doses of interferon alpha result in more effective clinical natural killer cell activation. J Clin Invest (1985) 0.93
An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma. J Biol Response Mod (1985) 0.93
Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas. Invest New Drugs (1990) 0.92
Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br J Cancer (2011) 0.91
The interferon refractory state. II. Biological characterization of a refractoriness-inducing protein. J Immunol (1975) 0.91
Interferons: biochemical, cell growth inhibitory, and immunological effects. Prog Hematol (1981) 0.91
Effects of interferons beta or gamma on neopterin biosynthesis and tryptophan degradation by human alveolar macrophages in vitro: synergy with lipopolysaccharide. Am J Respir Cell Mol Biol (1992) 0.90
Interferons: rationale for clinical trials in neoplastic disease. Ann Intern Med (1979) 0.90
G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer. Oncogene (2011) 0.89
Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta. J Immunother Emphasis Tumor Immunol (1993) 0.89
Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis. Int J Cancer (1997) 0.88
Effects of interferon beta ser and transforming growth factor beta on prostatic cell lines. J Urol (1991) 0.87
Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon. Clin Exp Immunol (1987) 0.87
Effects of amphotericin B and its methyl ester on the antiviral activity of polyinosinic:polycytidylic acid. Antimicrob Agents Chemother (1979) 0.87
Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. Cytokines Cell Mol Ther (1997) 0.87
Tamoxifen enhances interferon-regulated gene expression in breast cancer cells. Mol Cell Biochem (1997) 0.87
Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen. Cancer Res (1989) 0.87
Comparison of agar and agarose preparations for mengovirus plaque formation. Appl Microbiol (1970) 0.86
Effects of diethyldithiocarbamate, an inhibitor of interferon antiviral activity, upon human natural killer cells. J Immunol (1984) 0.86
Effect of influenza A virus on leukocyte histamine release. J Allergy Clin Immunol (1983) 0.86
Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity. Cancer Res (1984) 0.86
Progress toward therapeutic application of interferons, 1979-1983. Cancer (1984) 0.85
Hypertrophic osteoarthropathy and pregnancy. Ann Intern Med (1969) 0.85
Isoforms p69 and p100 of 2',5'-oligoadenylate synthetase induced differentially by interferons in vivo and in vitro. J Interferon Res (1993) 0.85
Tacaribe virus infection of the mouse: an immunopathologic disease model. Lab Invest (1974) 0.84
Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol (1992) 0.84
Modulation of 2',5'-oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedule, and route of administration. J Interferon Res (1986) 0.84
Plasma lipoprotein changes in humans induced by beta-interferon. Atherosclerosis (1987) 0.83
Absence of biological effects of orally administered interferon-beta ser. J Interferon Res (1992) 0.83
Recombinant interferon-gamma preserves human granulocyte bactericidal and chemoluminescence activities. J Infect Dis (1993) 0.83
John Locke, physician and author of the first Carolina Constitution. South Med J (1967) 0.83
Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine. J Natl Cancer Inst (1989) 0.83
Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J Urol (1984) 0.82
Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family. Clin Pharmacol Ther (2007) 0.81
Interferons and cancer: how the promise is being kept. Interferon (1983) 0.81
Binding of recombinant-produced interferon beta ser to human lymphoblastoid cells. Evidence for two binding domains. J Biol Chem (1987) 0.81
Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion. Cancer Res (1990) 0.81
Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon. Cancer Biother Radiopharm (1998) 0.81
Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion. Cancer Treat Rep (1983) 0.81
Antiproliferative effects of interferons on human melanoma cells in the human tumor colony-forming assay. J Interferon Res (1986) 0.80
Assessment of the antigenic response in humans to a recombinant mutant interferon beta. J Clin Immunol (1987) 0.80
Preclinical and clinical studies of interferons and interferon inducers in breast cancer. Cancer (1984) 0.80
Enhancement of infectivity of encephalomyocarditis virus RNA by amphotericin B methyl ester. J Gen Virol (1979) 0.80
Induced proteins in human peripheral mononuclear cells over a range of clinically tolerable doses of interferon-gamma. J Interferon Res (1989) 0.80
Interferon-alpha-n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma. J Biol Response Mod (1990) 0.80
Effects of thorotrast on humoral antibody, viral multiplication, and interferon during infection with St. Louis encephalitis virus in mice. J Infect Dis (1971) 0.79